NAGE vs. ALVO, BHC, CDTX, BEAM, TARS, IDYA, ARQT, IBRX, BLTE, and IRON
Should you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Alvotech (ALVO), Bausch Health Cos (BHC), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Arcutis Biotherapeutics (ARQT), ImmunityBio (IBRX), Belite Bio (BLTE), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry.
Niagen Bioscience vs. Its Competitors
Niagen Bioscience (NASDAQ:NAGE) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Niagen Bioscience has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500.
Niagen Bioscience has higher earnings, but lower revenue than Alvotech. Niagen Bioscience is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
Niagen Bioscience currently has a consensus target price of $13.42, suggesting a potential upside of 87.43%. Alvotech has a consensus target price of $14.00, suggesting a potential upside of 62.04%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Niagen Bioscience is more favorable than Alvotech.
In the previous week, Niagen Bioscience had 5 more articles in the media than Alvotech. MarketBeat recorded 12 mentions for Niagen Bioscience and 7 mentions for Alvotech. Alvotech's average media sentiment score of 0.85 beat Niagen Bioscience's score of -0.02 indicating that Alvotech is being referred to more favorably in the news media.
15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Niagen Bioscience has a net margin of 15.24% compared to Alvotech's net margin of 11.26%. Niagen Bioscience's return on equity of 23.12% beat Alvotech's return on equity.
Summary
Niagen Bioscience beats Alvotech on 11 of the 16 factors compared between the two stocks.
Get Niagen Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Niagen Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:NAGE) was last updated on 10/7/2025 by MarketBeat.com Staff
